Interested parties may present the agency with any evidence that they assume has bearing on this concern. Our persevering with evaluate of data that has been submitted up to now has not triggered us to vary our conclusions. A. The agency has acquired reviews of adverse occasions in patients utilizing cannabis or cannabis-derived products to treat medical situations. The FDA evaluations such stories and can continue to monitor antagonistic occasion stories for any security indicators, with a focus on critical adverse effects. Consumers and healthcare suppliers can report adverse occasions associated with cannabis or cannabis-derived merchandise via the FDA’s MedWatch reporting system, both online or by cellphone at FDA-1088. Reuters…